TAO Synergies (TAOX) Revenue (2025 - 2026)
TAO Synergies' (TAOX) quarterly Revenue came in at $88626.0 in Q2 2026, up 2136.9% on a YoY basis from $3962.0 in Q2 2025, and down 77.2% quarter-over-quarter from $388774.0 in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Revenue (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Revenue for 2 consecutive years, with $88626.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue rose 2136.9% year-over-year to $88626.0; the trailing twelve-month figure through Jun 2026 stood at $772499.0 (changed N/A YoY), and the FY2025 full-year result was $299061.0, changed N/A from the prior year.
- Revenue slipped to $88626.0 in Q2 2026 per TAOX's latest filing, from $388774.0 in the prior quarter.
- Across five years, Revenue topped out at $388774.0 in Q1 2026 and bottomed at $3962.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.33 Bn | 198.34 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.55 Bn | 177.37 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 132.28 Bn | 124.42 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.90 Bn | 73.91 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.14 Bn | 55.96 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 55.12 Bn | 49.98 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.85 Bn | 30.54 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.89 Bn | 29.89 Bn | 1.16 Mn | 1.44 Mn |
| 10 | TAO Synergies | 31.06 Mn | 31.06 Mn | - | 88,626.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 88,626.00 |
| Mar 31, 2026 | 388,774.00 |
| Dec 31, 2025 | 91,728.00 |
| Sep 30, 2025 | 203,371.00 |
| Jun 30, 2025 | 3,962.00 |